Lowest Price Guaranteed From USD 4,799
Published
January 2023
Pages
363
View Count
11429
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The TCR therapy market is estimated to be worth $0.03 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 51% during the forecast period, mainly driven by the need for targeted cancer treatment for solid tumors. Modified T-cell receptor (TCR) based therapy is an emerging class of adoptive cell therapy that employs genetically modified lymphocytes to target specific tumor markers. Their tumor cell killing efficacy may be primarily attributed to the fact that they are pre-sensitized to cancer specific antigens; this enables such interventions to selectively target and eliminate tumor cells from the body of a host with negligible treatment-related side effects. Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various hematological cancers and solid tumors. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the T cell receptor therapy market is likely to witness significant growth during the forecast period.
The Global TCR Therapy Market (2nd Edition), 2022-2035: Distribution by Target Indication (Nasopharyngeal Carcinoma, Multiple Myeloma, Head and Neck Carcinoma, Sarcoma, Melanoma, Acute Myeloid Leukemia, Lung Cancer, Ovarian Cancer, and Merkel Cell Cancer), Target Antigen (NY-ESO-1, EBV, gp100, and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035 report features an extensive study of the current market landscape, market size and future potential of TCR therapies. The market report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the biopharmaceutical industry. The report answers many key questions related to this market:
Modified T cell receptor therapy, an upcoming class of cell-based interventions, is a promising therapeutic modality. TCR therapy is a novel segment within the T-cell therapy market, of which CAR T cell therapy is the biggest segment. Similar to other T-cell based interventions (such as CAR T cell therapy and tumor infiltrating lymphocytes), TCR therapies are designed to target the underlying causes (or primary mediators) of a clinical condition. All the approved CAR T cell therapies target hematological cancer; however, solid tumor treatment presents an opportunity area for the cell therapy developers. Additionally, this emerging class of biologics is believed to possess the potential to cater to unmet pharmacological needs across both oncological and non-oncological disorders, even those where small molecule drugs have proven to be inadequate. Although T cell receptor based immunotherapies are still considered an experimental approach, several clinical trials demonstrate the efficacy and therapeutic superiority of TCR therapies. The TCR therapy market growth will essentially be driven by their development for the high unmet needs in solid tumor treatment.
Presently, more than 100 industry and non-industry players across the globe are evaluating the potential of over 190 T cell receptor based immunotherapies for the treatment of various oncological and non-oncological disorders. It is worth highlighting that, in January 2022, the FDA approved the first TCR therapy, Kimmtrak® (Immunocore), for the treatment of adult patients with unresectable or metastatic uveal melanoma. More than 90% of the therapy candidates that are being developed to target a wide range of disease indications are autologous in nature. Only few of the candidates are allogeneic cell therapy. Further, NY-ESO-1 and MAGE emerged as the most popular target antigens in this industry. As per Adaptimmune, more than 84,000 patients annually die from MAGE-A4 positive tumors in the US and EU together. The company’s TCR T cell therapy targeting MAGE-A4, afami-cel, is expected to receive FDA approval for treatment of synovial sarcoma in 2024.
The TCR therapies market is also evolving with the companies working on development of next generation engineered TCR T cell therapies. Medigene is developing multiple TCR T cell therapies comprising of PD1-41BB switch receptor, helping the TCR therapies overcome challenges posed by the tumor microenvironment. Their therapies are currently in preclinical development. Such technological advancements will ensure development of safer and more efficacious T cell receptor therapies, driving the market growth during the forecast period.
The growing interest in this field is reflected in the notable increase in partnerships inked (close to 140 deals inked in the past decade; CAGR 23%) by several industry players and academic / research institutes. Big pharmaceutical companies are also entering the TCR therapy market through partnerships or M&A activity. In November 2022, AstraZeneca announced its plans to acquire TCR T cell therapy company Neogene Therapeutics for a sum of USD 320 million, which includes USD 200 million upfront payment of deal closure.
Additionally, various investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 11 billion across 140 instances, since 2007. Further, in the last 10 years, close to 110 clinical trials have been registered across different geographies for the evaluation of TCR therapies. MD Anderson is expected to begin a phase I clinical trial for its TCR NK cell therapy for advanced synovial sarcoma by the end of 2023. The T cell receptor therapy comprise cord-blood derived NK cells that express TCR against NY-ESO-1 antigen. The sponsor plans to enrol 44 patients for this clinical trial. Mostly driven by the need for effective treatment options for cancer, the TCR therapy pipeline is expected to steadily grow over the forecast period. Moreover, clinical success is likely to draw in investments that are likely to support the ongoing and anticipated therapy development initiatives. As the TCR companies move the products to clinical development, funding from big pharmaceutical companies and venture funding will support the market growth.
With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of 51% in the next decade. Specifically, in terms of target indication, the market is anticipated to be driven by nasopharyngeal carcinoma, multiple myeloma, and head and neck carcinoma. Additionally, more than 80% of the market is anticipated to be captured by players based in Europe and Asia-Pacific in 2035. Overall, we are led to believe that the global TCR-based therapy market is poised to witness significant growth in the foreseen future.
Examples of key companies engaged in the T cell therapy market (which have also been captured in this report) include Adaptimmune Therapeutics, Alaunos Therapeutics, blubird bio, Bristol Myers Squibb, Cellular Biomedicine Group, China Immunotech, Gilead Sciences, GlaxoSmithKline, Immatics, Immunocore, Intellia Therapeutics, Lion TCR, Takara Bio, TCRCure Biopharma, and Zelluna Immunotherapy.
Several recent developments have taken place in the field of TCR therapies. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The market reports presents an in-depth analysis of the various firms / organizations that are engaged in this industry, across different segments as defined in the below table:
| Key Report Attributes | Details | |
|
Base Year |
2022 |
|
|
Forecast Period |
2022 - 2035 |
|
|
CAGR |
51% |
|
|
Target Indications |
Nasopharyngeal Carcinoma, Multiple Myeloma, Head and Neck Carcinoma, Sarcoma, Melanoma, Acute Myeloid Leukemia, Lung Cancer, Ovarian Cancer, Merkel Cell Cancer |
|
|
Target Antigens |
NY-ESO-1, EBV, gp100 |
|
|
Key Players |
GlaxoSmithKline, China Immunotech, Xinqiao Hospital of Chongqing, TCRCure Biopharma, Adaptimmune Therapeutics, Immunocore, Intellia Therapeutics, Takara Bio, bluebird bio | |
|
Key Geographical Regions |
North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa (MENA), Rest of the World |
|
|
Key Companies Profiled |
Adaptimmune Therapeutics, Alaunos Therapeutics, Bristol Myers Squibb, Cellular Biomedicine, Gilead Biosciences, GlaxoSmithKline, Immatics, Immunocore, Lion TCR, Takara Bio, Zelluna Immunotherapy |
|
| Customization Scope | 15% Free Customization Option | |
| Powerpoint Presentation | Complimentary | |
| Excel Data Packs | Complimentary: Market Landscape Analysis, Clinical Trial Analysis, KOL Analysis, Partnership and Collaboration Analysis, Funding and Investment Analysis, Patent Analysis, Market Forecast and Opportunity Analysis | |
Amongst other elements, the market report includes:
One of the key objectives of the market report was to estimate the current opportunity, market size and the future growth potential of TCR therapies over the forecast period. Based on several parameters, such as target consumer segments, region-specific adoption rates, and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the forecast period 2022-2035. The market research report also includes likely sales forecasts of TCR therapies that are in the mid- to late stages of development. Additionally, it features market size projections for the overall TCR therapy market, wherein both the current and upcoming opportunity is segmented across target indication (nasopharyngeal carcinoma, multiple myeloma, head and neck carcinoma, sarcoma, melanoma, acute myeloid leukemia, lung cancer, ovarian cancer and merkel cell cancer), target antigen (NY-ESO-1, EBV, gp100 and others), key players and key geographical regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base, and optimistic scenarios, which represent different tracks of the industry’s evolution.
The opinions and insights presented in this market analysis were influenced by discussions conducted with several stakeholders in this industry. The market report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Chapter Overview
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. T Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods
3.7. T-Cell Receptor (TCR)-based Cell Therapy
3.7.1. Development History
3.7.2. Anatomical Layout of TCR
3.7.3. Development of TCR Therapy
3.7.4. Differences between CAR-T and TCR Therapies
3.8. Concluding Remarks
4. TCR THERAPIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. TCR Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Key Target Indication
4.2.6. Analysis by Key Target Antigen
4.2.7. Analysis by Source of T-Cells
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Phase of Development and Route of Administration
4.2.10. Analysis by Dosing Frequency
4.2.11. Analysis by Target Patient Segment
4.2.12. Analysis by Type of Therapy
4.2.13. Analysis by Phase of Development and Type of Therapy
4.2.14. Most Active Industry Players: Analysis by Number of TCR Therapies
4.2.15. Most Active Non-Industry Players: Analysis by Number of TCR Therapies
4.3. TCR Therapies: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
5. POPULAR TARGET ANTIGEN ANALYSIS
5.1. Chapter Overview
5.2. Competitive Analysis: Popular Target Antigens of TCR Therapies
5.2.1. Popular Targets Related to Hematological Malignancies
5.2.2. Popular Targets Related to Solid Tumors
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. TCR Therapies: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.3. Analysis by Trial Status
6.3.4. Analysis by Trial Registration Year and Trial Status
6.3.5. Analysis by Trial Phase
6.3.6. Analysis of Enrolled Patient Population by Trial Phase
6.3.7. Analysis by Target Patient Segment
6.3.8. Analysis by Type of Sponsor / Collaborator
6.3.9. Analysis by Study Design
6.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.3.12. Word Cloud Representation Analysis: Emerging Focus Areas
6.3.13. Analysis of Clinical Trials by Geography
6.3.14. Analysis of Enrolled Patient Population by Geography
7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. TCR Therapies: Key Opinion Leaders
7.4.1. Analysis by Type of Organization
7.4.2. Analysis by Affiliated Organization
7.4.3. Analysis by Qualification
7.4.4. Analysis by Geographical Location of KOLs
7.4.5. KOL Activeness versus KOL Strength
7.4.6. Most Prominent KOLs: Analysis by RA score
7.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
8. T CELL RECEPTOR THERAPY PROFILES
8.1. Chapter Overview
8.2. Kimmtrak® / IMCgp100 / Tebentafusp (Immunocore)
8.2.1. Therapy Overview
8.2.2. Clinical Trial Information
8.2.3. Clinical Trial Endpoints
8.2.4. Clinical Trial Results
8.2.5. Estimated Sales Revenues
8.3. GSK3377794 / NY-ESO-1C259 T-cells / Letetresgene Autoleucel (GlaxoSmithKline)
8.3.1. Therapy Overview
8.3.2. Clinical Trial Information
8.3.3. Clinical Trial Endpoints
8.3.4. Clinical Trial Results
8.3.5. Estimated Sales Revenues
8.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
8.4.1. Therapy Overview
8.4.2. Clinical Trial Information
8.4.3. Clinical Trial Endpoints
8.4.4. Clinical Trial Results
8.4.5. Estimated Sales Revenues
8.5. JTCR016 (Juno Therapeutics)
8.5.1. Therapy Overview
8.5.2. Clinical Trial Information
8.5.3. Clinical Trial Endpoints
8.6. TBI-1301 (Takara Bio)
8.6.1. Therapy Overview
8.6.2. Clinical Trial Information
8.6.3. Clinical Trial Endpoints
8.6.4. Clinical Trial Results
8.6.5. Estimated Sales Revenues
8.7. MDG1011 (Medigene)
8.7.1. Therapy Overview
8.7.2. Clinical Trial Information
8.7.3. Clinical Trial Endpoints
8.7.4. Clinical Trial Results
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. TCR Therapies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year of Partnership and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Most Popular Products: Analysis by Number of Partnerships
9.3.6. Most Active Industry Players: Analysis by Number of Partnerships
9.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
9.3.8. Analysis by Geography
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. International and Local Deals
10 FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. TCR Therapies: Funding and Investment Analysis
10.3.1. Analysis of Instances by Year
10.3.2. Analysis of Amount Invested by Year
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Type of Investor
10.3.5. Most Active Players: Analysis by Number of Instances
10.3.6. Most Active Investors: Analysis by Amount Invested
10.3.7. Analysis of Amount Invested by Geography
10.3.8. Most Active Investors: Analysis by Number of Funding Instances
11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. TCR Therapies: Patent Analysis
11.3.1. Analysis by Patent Publication Year
11.3.2. Analysis By Patent Application Year
11.3.3. Analysis by Geography
11.3.4. Analysis by Type of Player
11.3.5. Analysis by CPC Symbols
11.3.6. Analysis by Key Focus Area
11.3.7. Leading Player: Analysis by Number of Patents
11.3.8. TCR Therapies: Patent Benchmarking
11.3.9. Analysis By Patent Characteristics
11.3.10. TCR Therapies: Patent Valuation
12. CASE STUDY: CELL THERAPY MANUFACTURING
12.1. Chapter Overview
12.2. Overview of Cell Therapy Manufacturing
12.3. Cell Therapy Manufacturing Models
12.3.1. Centralized Manufacturing Model
12.3.2. Decentralized Manufacturing Model
12.4. Scalability of Cell Therapy Manufacturing Processes
12.4.1. Scale-Up
12.4.2. Scale-Out
12.5. Types of Cell Therapy Manufacturers
12.6. Key Challenges Related to Manufacturing of Cell Therapies
12.7. Important Factors for Cell Therapy Manufacturing
12.7.1. Characterization
12.7.2. Cost of Goods
12.8. Automation of Cell Therapy Manufacturing Processes
12.9. Cell Therapy Manufacturing Supply Chain
12.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
12.11. Regulatory Landscape
12.12. Future Perspectives
13. COST PRICE ANALYSIS
13.1. Chapter Overview
13.2. Factors Contributing to the High Price of Cell / Gene Therapies
13.3. Pricing Models for T-Cell Immunotherapies
13.3.1. Based on Associated Costs
13.3.2. Based on Availability of Competing Products
13.3.3. Based on Patient Segment
13.3.4. Based on Opinions of Industry Experts
13.4. Reimbursement related Considerations for T-cell Immunotherapies
13.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology
14.4. Global TCR Therapy Market, 2022-2035
14.4.1. TCR Therapy Market: Analysis by Target Indication
14.4.2. TCR Therapy Market: Analysis by Target Antigen
14.4.3. TCR Therapy Market: Analysis by Key Players
14.4.4. TCR Therapy Market: Distribution by Geography
14.4.5. Product Wise Sales Forecast
14.4.5.1. Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore)
14.4.5.1.1. Sales Forecast (USD Million)
14.4.5.1.2. Net Present Value (USD Million)
14.4.5.1.3. Value Creation Analysis
14.4.5.2. GSK3377794 (GlaxoSmithKline)
14.4.5.2.1. Sales Forecast (USD Million)
14.4.5.2.2. Net Present Value (USD Million)
14.4.5.2.3. Value Creation Analysis
14.4.5.3. YT-E001 (China Immunotech)
14.4.5.3.1. Sales Forecast (USD Million)
14.4.5.3.2. Net Present Value (USD Million)
14.4.5.3.3. Value Creation Analysis
14.4.5.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
14.4.5.4.1. Sales Forecast (USD Million)
14.4.5.4.2. Net Present Value (USD Million)
14.4.5.4.3. Value Creation Analysis
14.4.5.5. EBV-specific TCR-T cell with Anti-PD1 Aauto-secreted Element (TCRCure Biopharma)
14.4.5.5.1. Sales Forecast (USD Million)
14.4.5.5.2. Net Present Value (USD Million)
14.4.5.5.3. Value Creation Analysis
14.4.5.6. NTLA-5001 (Intellia Therapeutics)
14.4.5.6.1. Sales Forecast (USD Million)
14.4.5.6.2. Net Present Value (USD Million)
14.4.5.6.3. Value Creation Analysis
14.4.5.7. TBI-1301 (Takara Bio)
14.4.5.7.1. Sales Forecast (USD Million)
14.4.5.7.2. Net Present Value (USD Million)
14.4.5.7.3. Value Creation Analysis
14.4.5.8. LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology)
14.4.5.8.1. Sales Forecast (USD Million)
14.4.5.8.2. Net Present Value (USD Million)
14.4.5.8.3. Value Creation Analysis
14.4.5.9. FH-MCVA2TCR (TCRCure Biopharma)
14.4.5.9.1. Sales Forecast (USD Million)
14.4.5.9.2. Net Present Value (USD Million)
14.4.5.9.3. Value Creation Analysis
15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Kimmtrak: Promotional Analysis
15.3.1. Drug Overview
15.3.2. Product Website Analysis
15.3.2.1. Message for Healthcare Professionals
15.3.2.2. Message for Patients
15.3.2.3. Informative Downloads
15.3.3. Patient Support Services
16. COMPANY PROFILES
16.1. Chapter Overview
16.2. Adaptimmune Therapeutics
16.3. Alaunos Therapeutics
16.4. Company Profiles
16.5. Bristol Myers Squibb
16.6. Cellular Biomedicine Group
16.7. Gilead Sciences
16.8. Cellular Biomedicine Group
16.9. GlaxoSmithKline
16.10. Immatics
16.11. Immunocore
16.12. Lion TCR
16.13. Takara Bio
16.14. Zelluna immunotherapy
17. CONCLUDING REMARKS
18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Celyad
18.2.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncology
18.3. Kite Pharma
18.3.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
18.4. Lion TCR
18.4.1. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
18.5. TxCell
18.5.1. Interview Transcript: Miguel Forte, Chief Operating Officer
19. APPENDIX 1: TABULATED DATA
20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 TCR Therapies: Development Process
Figure 4.1 TCR Therapies: Distribution by Type of Developer
Figure 4.2 TCR Therapies: Distribution by Phase of Development
Figure 4.3 TCR Therapies: Distribution by Therapeutic Area
Figure 4.4 TCR Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 TCR Therapies: Distribution by Key Target Indications
Figure 4.6 TCR Therapies: Distribution by Key Target Antigens
Figure 4.7 TCR Therapies: Distribution by Source of T-Cells
Figure 4.8 TCR Therapies: Distribution by Phase of Development and Source of T-Cells
Figure 4.9 TCR Therapies: Distribution by Route of Administration
Figure 4.10 TCR Therapies: Distribution by Dosing Frequency
Figure 4.11 TCR Therapies: Distribution by Target Patient Segment
Figure 4.12 TCR Therapies: Distribution by Type of Therapy
Figure 4.13 Most Active Industry Players: Distribution by Number of TCR Therapies
Figure 4.14 Most Active Non-Industry Players: Distribution by Number of TCR Therapies
Figure 4.15 TCR Therapy Developers: Distribution by Year of Establishment
Figure 4.16 TCR Therapy Developers: Distribution by Company Size
Figure 4.17 TCR Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.18 TCR Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 TCR Therapies: Popular Targets in Hematological Malignancies
Figure 5.2 TCR Therapies: Popular Targets in Solid Tumors
Figure 6.1 Clinical Trial Analysis: Scope and Methodology
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2013-2022
Figure 6.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2022
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 6.6 Clinical Trial Analysis: Distribution of Trials by Trial Phase
Figure 6.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 6.8 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 6.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.10 Clinical Trial Analysis: Distribution by Study Design
Figure 6.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 6.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 6.13 Word Cloud Analysis: Emerging Focus Areas
Figure 6.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 6.15 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 6.16 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 6.17 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 7.1 KOL Analysis: Distribution by Type of Organization
Figure 7.2 KOL Analysis: Distribution by Affiliated Organization
Figure 7.3 KOL Analysis: Distribution by Qualification
Figure 7.4 KOL Analysis: Distribution by Geography
Figure 7.5 TCR-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 7.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 7.7 Most Prominent KOLs: Distribution by RA Score
Figure 7.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 7.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 8.1 Kimmtrak®: Estimated Sales Revenues
Figure 8.2 GSK3377794: Estimated Sales Revenues
Figure 8.3 ADP-A2M4: Estimated Sales Revenues
Figure 8.4 JTCR016: Estimated Sales Revenues
Figure 8.5 TBI-1301: Estimated Sales Revenues
Figure 8.6 MDG1011: Estimated Sales Revenues
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
Figure 9.4 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2015-2022
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.6 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Figure 9.7 Most Popular Products: Distribution by Number of Partnerships
Figure 9.8 Most Active Industry Players: Distribution by Number of Partnerships
Figure 9.9 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 9.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 9.11 Partnerships and Collaborations: International and Local Deals
Figure 10.1 Funding and Investment Analysis: Cumulative Year-wise Distribution of Instances, Pre-2018-2022
Figure 10.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, Pre-2018-2022 (USD Million)
Figure 10.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 10.5 Funding and Investment Analysis: Distribution by Type of Investor
Figure 10.6 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 10.7 Most Active Players: Distribution by Number of Instances
Figure 10.8 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 10.9 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 11.3 Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 11.4 Patent Analysis: Cumulative Year-wise Distribution of Granted Patents
Figure 11.5 Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
Figure 11.6 Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents
Figure 11.7 Patent Analysis: Distribution by Geography
Figure 11.8 Patent Analysis: Distribution by Type of Player
Figure 11.9 Patent Analysis: Distribution by CPC Symbols
Figure 11.10 Patent Analysis: Key Focus Area
Figure 11.11 Leading Industry Players: Distribution by Number of Patents
Figure 11.12 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.13 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.14 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
Figure 11.15 Patent Analysis: Distribution by Patent Age
Figure 11.14 TCR-based Cell Therapies: Patent Valuation Analysis
Figure 12.1 Steps for Manufacturing Cell Therapies
Figure 12.2 Centralized Manufacturing: Process Model
Figure 12.3 Decentralized Manufacturing: Process Model
Figure 12.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 12.5 Cell Therapy: Challenges and Drivers
Figure 12.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 12.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 12.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 13.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 14.1 Global TCR-based Therapies Market, 2022-2035 (USD Billion)
Figure 14.2 TCR Therapy Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 14.3 TCR Therapy Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Figure 14.4 TCR Therapy Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 14.5 TCR Therapy Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 14.6 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore) Sales Forecast, till 2035 (USD Million)
Figure 14.7 GSK3377794 (GlaxoSmithKline) Sales Forecast, till 2035 (USD Million)
Figure 14.8 YT-E001 (China Immunotech) Sales Forecast, till 2035 (USD Million)
Figure 14.9 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.10 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 14.11 NTLA-5001 (Intellia Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.12 TBI-1301 (Takara Bio) Sales Forecast, till 2035 (USD Million)
Figure 14.13 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology) Sales Forecast, till 2035 (USD Million)
Figure 15.1 Channels Used for Promotional Campaigns
Figure 15.2 Product Website Analysis: Kimmtrak®, Messages for Healthcare Professional
Figure 15.3 Product Website Analysis: Kimmtrak®, Messages for Patients
Figure 15.4 Product Website Analysis: Kimmtrak®, Kimmtrak Connect
Figure 17.1 Concluding Remarks: Market Landscape
Figure 17.2 Concluding Remarks: Clinical Trial Analysis
Figure 17.3 Concluding Remarks: Key Opinion Leaders
Figure 17.4 Concluding Remarks: Partnerships & Collaborations
Figure 17.5 Concluding Remarks: Funding and Investment Analysis
Figure 17.6 Concluding Remarks: Patent Analysis
Figure 17.7 Concluding Remarks: Market Forecast
Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody-based Cancer Therapeutics
Table 3.3 Retroviral Vectors: Salient Features
Table 3.4 Lentiviral Vectors: Salient Features
Table 3.5 CAR-T Cell and TCR Therapies: Key Differences
Table 4.1 TCR Therapies: Clinical Pipeline
Table 4.2 TCR Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 4.3 TCR Therapies: Preclinical Pipeline
Table 4.4 List of TCR-based Developers
Table 8.1 TCR Therapies: List of Therapies Profiled
Table 8.2 Therapy Profile: Kimmtrak (Immunocore)
Table 8.3 Kimmtrak: Clinical Trial Information
Table 8.4 Kimmtrak: Clinical Trial Endpoints
Table 8.5 Kimmtrak: Clinical Trial Results
Table 8.6 Therapy Profile: GSK3377794 (GlaxoSmithKline)
Table 8.7 GSK3377794: Clinical Trial Information
Table 8.8 GSK3377794: Clinical Trial Endpoints
Table 8.9 GSK3377794: Clinical Trial Results
Table 8.10 Therapy Profile: ADP-A2M4 (Adaptimmune Therapeutics)
Table 8.11 ADP-A2M4: Clinical Trial Information
Table 8.12 ADP-A2M4: Clinical Trial Endpoints
Table 8.13 ADP-A2M4: Clinical Trial Results
Table 8.14 Therapy Profile: JTCR016 (Juno Therapeutics (Bristol Myers Squibb))
Table 8.15 JTCR016: Clinical Trial Information
Table 8.16 JTCR016: Clinical Trial Endpoints
Table 8.17 Therapy Profile: TBI-1301 (Takara Bio)
Table 8.18 TBI-1301: Clinical Trial Information
Table 8.19 TBI-1301: Clinical Trial Endpoints
Table 8.20 TBI-1301: Clinical Trial Results
Table 8.21 Therapy Profile: MDG108 (Medigene)
Table 8.22 MDG108: Clinical Trial Information
Table 8.23 MDG108: Clinical Trial Endpoints
Table 8.24 MDG108: Clinical Trial Results
Table 9.1 List of Partnerships and Collaborations, 2005-2022
Table 10.1 List of Funding and Investments, 2007-2022
Table 10.2 Funding and Investment Analysis: Summary of Investments
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: Most Popular CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 12.1 Assessment Strategies for Different Manufacturing Processes
Table 12.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 12.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 13.1 Price of Marketed Gene / Cell Therapies
Table 13.2 Price of Marketed Targeted Drugs
Table 13.3 TCR Therapies: Expert Opinions on Pricing
Table 13.4 TCR Therapies: Reimbursement Landscape
Table 14.1 TCR Therapies: List of Forecasted Molecules
Table 14.2 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore): Net Present Value (USD Million)
Table 14.3 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore): Value Creation Analysis (USD Million)
Table 14.4 GSK3377794 (GlaxoSmithKline): Net Present Value (USD Million)
Table 14.5 GSK3377794 (GlaxoSmithKline): Value Creation Analysis (USD Million)
Table 14.6 YT-E001 (China Immunotech): Net Present Value (USD Million)
Table 14.7 YT-E001 (China Immunotech): Value Creation Analysis (USD Million)
Table 14.8 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Net Present Value (USD Million)
Table 14.9 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Value Creation Analysis (USD Million)
Table 14.10 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Net Present Value (USD Million)
Table 14.11 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 14.12 NTLA-5001 (Intellia Therapeutics): Net Present Value (USD Million)
Table 14.13 NTLA-5001 (Intellia Therapeutics): Value Creation Analysis (USD Million)
Table 14.14 TBI-1301 (Takara Bio): Net Present Value (USD Million)
Table 14.15 TBI-1301 (Takara Bio): Value Creation Analysis (USD Million)
Table 14.16 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Net Present Value (USD Million)
Table 14.17 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Value Creation Analysis (USD Million)
Table 14.18 FH-MCVA2TCR (TCRCure Biopharma): Net Present Value (USD Million)
Table 14.19 FH-MCVA2TCR (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 15.1 Kimmtrak®: Drug Overview
Table 16.1 Leading TCR Therapy Developers
Table 16.2 Adaptimmune Therapeutics: Company Profile
Table 16.3 Alaunos Therapeutics: Company Profile
Table 16.4 Bristol Myers Squibb: Company Profile
Table 16.5 Cellular Biomedicine Group: Company Profile
Table 16.6 Gilead Sciences: Company Profile
Table 16.7 GlaxoSmithKline: Company Profile
Table 16.8 Immatics: Company Profile
Table 16.9 Immunocore: Company Profile
Table 16.10 Lion TCR: Company Profile
Table 16.11 Takara Bio: Company Profile
Table 16.12 Zelluna Immunotherapy: Company Profile
Table 19.1 TCR Therapies: Distribution by Type of Developer
Table 19.2 TCR Therapies: Distribution by Phase of Development
Table 19.3 TCR Therapies: Distribution by Therapeutic Area
Table 19.4 TCR Therapies: Distribution by Phase of Development and Therapeutic Area
Table 19.5 TCR Therapies: Distribution by Key Target Indications
Table 19.6 TCR Therapies: Distribution by Key Target Antigens
Table 19.7 TCR Therapies: Distribution by Source of T-Cells
Table 19.8 TCR Therapies: Distribution by Phase of Development and Source of T-Cells
Table 19.9 TCR Therapies: Distribution by Route of Administration
Table 19.10 TCR Therapies: Distribution by Dosing Frequency
Table 19.11 TCR Therapies: Distribution by Target Patient Segment
Table 19.12 TCR Therapies: Distribution by Type of Therapy
Table 19.13 Most Active Industry Players: Analysis by Number of TCR Therapies
Table 19.14 Most Active Non-Industry Players: Distribution by Number of TCR Therapies
Table 19.15 TCR Therapy Developers: Distribution by Year of Establishment
Table 19.16 TCR Therapy Developers: Distribution by Company Size
Table 19.17 TCR Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 19.18 TCR Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 19.19 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2013-2022
Table 19.20 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2022
Table 19.21 Clinical Trial Analysis: Distribution by Trial Status
Table 19.22 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Table 19.23 Clinical Trial Analysis: Distribution of Trials by Trial Phase
Table 19.24 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 19.25 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 19.26 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 19.27 Clinical Trial Analysis: Distribution by Study Design
Table 19.28 Most Active Industry Players: Distribution by Number of Registered Trials
Table 19.29 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 19.30 Clinical Trial Analysis: Distribution of Trials by Geography
Table 19.31 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 19.32 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 19.33 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 19.34 KOL Analysis: Distribution by Type of Organization
Table 19.35 KOL Analysis: Distribution by Affiliated Organization
Table 19.36 KOL Analysis: Distribution by Qualification
Table 19.37 KOL Analysis: Distribution by Geography
Table 19.38 Most Prominent KOLs: Distribution by RA Score
Table 19.39 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 19.40 Kimmtrak®: Estimated Sales Revenues
Table 19.41 GSK3377794: Estimated Sales Revenues
Table 19.42 ADP-A2M4: Estimated Sales Revenues
Table 19.43 JTCR016: Estimated Sales Revenues
Table 19.44 TBI-1301: Estimated Sales Revenues
Table 19.45 MDG1011: Estimated Sales Revenues
Table 19.46 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 19.47 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.48 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
Table 19.49 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.50 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Table 19.51 Most Popular Products: Distribution by Number of Partnerships
Table 19.52 Most Active Industry Players: Distribution by Number of Partnerships
Table 19.53 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 19.54 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 19.55 Partnerships and Collaborations: Distribution of International and Local Deals
Table 19.56 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Table 19.57 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 - 2022 (USD Million)
Table 19.58 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 19.59 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 19.60 Funding and Investment Analysis: Distribution by Type of Investor
Table 19.61 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
Table 19.62 Most Active Players: Distribution by Number of Instances
Table 19.63 Most Active Players: Distribution by Amount Invested (USD Million)
Table 19.64 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 19.65 Patent Analysis: Distribution by Type of Patent
Table 19.66 Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 19.67 Patent Analysis: Cumulative Distribution Patent Application Year
Table 19.68 Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 19.69 Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
Table 19.70 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications
Table 19.71 Patent Analysis: Distribution by Geography
Table 19.72 Patent Analysis: Distribution by Type of Player
Table 19.73 Patent Analysis: Distribution by CPC Symbols
Table 19.74 Leading Industry Players: Distribution by Number of Patents
Table 19.75 Leading Non-Industry Players: Distribution by Number of Patents
Table 19.76 Leading Patent Assignees: Distribution by Number of Patents
Table 19.77 Patent Analysis: Distribution by Patent Age
Table 19.78 TCR Therapies: Patent Valuation Analysis
The following companies and organizations have been mentioned in the report:
Source 1: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01115-0
Source 2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391541/
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES